Recently Featured

Takeda to Pay $13.6 Million to Settle Kickback Allegations

June 7, 2026
Takeda Pharmaceuticals has agreed to pay $13.6 million to settle allegations of paying kickbacks to physicians to promote its antidepressant, Trintellix, leading to violations of federal law and false claims submitted to Medicaid, as announced by the U.S. Department of Justice. The allegations span from January 2014 to October 2020, during which Takeda purportedly provided…

FDA hold puts Aardvark Prader-Willi drug in limbo

June 7, 2026
Aardvark Pharmaceuticals is facing a significant setback as the FDA has placed a hold on its Prader-Willi syndrome drug, leaving the company in a precarious position. This regulatory action follows safety concerns raised during the late-stage clinical trials, which has now resulted in the unblinding of the study. The implications of this hold extend beyond…

ECO 2026: Indirect Comparison Favors Wegovy Pill Over Foundayo

June 7, 2026
At ECO 2026, a post-hoc indirect treatment comparison revealed that Wegovy, an oral GLP-1 receptor agonist (RA), demonstrates superior efficacy over Foundayo in the context of chronic weight management. This analysis is particularly relevant as both medications have recently received approval in the US, positioning them as competitive options in the growing market for obesity…

ASGCT Q1 Landscape Report Highlights Growth in Gene and RNA Therapy

June 7, 2026
BOSTON – The American Society for Gene and Cell Therapy (ASGCT) has released its latest Landscape Report for the first quarter of 2026, revealing a robust expansion in the gene and RNA therapy sectors. CEO David Barrett, JD, noted that there are currently 42 gene therapies, 38 RNA therapies, and 76 non-genetically modified cell therapies…

Ongoing Cases